## Caroline Aspord

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4779545/publications.pdf

Version: 2024-02-01

304602 2,341 43 22 citations h-index papers

g-index 43 43 43 3632 docs citations times ranked citing authors all docs

276775

41

#	Article	IF	CITATIONS
1	Diversification of circulating and tumorâ€infiltrating plasmacytoid DCs towards the P3 (CD80 <sup>+</sup> PDL1 <sup>â^'</sup> )â€pDC subset negatively correlated with clinical outcomes in melanoma patients. Clinical and Translational Immunology, 2022, 11, e1382.	1.7	6
2	Impaired Antitumor Immune Response in <i>MYCN</i> -amplified Neuroblastoma Is Associated with Lack of CCL2 Secretion and Poor Dendritic Cell Recruitment. Cancer Research Communications, 2022, 2, 577-589.	0.7	3
3	Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and $\hat{I}^{3}\hat{I}$ T cells in melanoma patients, which impacts clinical outcomes. Clinical and Translational Immunology, 2021, 10, e1329.	1.7	7
4	Reply to Comment on "Jilkova, Z.M.; et al. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges―Cancers 2019, 11, 1554. Cancers, 2020, 12, 2673.	1.7	4
5	BDCA1 <sup>+</sup> cDC2s, BDCA2 <sup>+</sup> pDCs and BDCA3 <sup>+</sup> cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients. Clinical and Translational Immunology, 2020, 9, e1190.	1.7	16
6	Hepatitis B virus exploits Câ€type lectin receptors to hijack cDC1s, cDC2s and pDCs. Clinical and Translational Immunology, 2020, 9, e1208.	1.7	3
7	Tâ€cell receptor diversity as a prognostic biomarker in melanoma patients. Pigment Cell and Melanoma Research, 2020, 33, 612-624.	1.5	18
8	An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial. Oncolmmunology, 2020, 9, 1738812.	2.1	38
9	Potent Bidirectional Cross-Talk Between Plasmacytoid Dendritic Cells and γÎT Cells Through BTN3A, Type I/II IFNs and Immune Checkpoints. Frontiers in Immunology, 2020, 11, 861.	2.2	17
10	Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. Cancers, 2019, 11, 1554.	1.7	73
11	The features of circulating and tumor-infiltrating $\hat{I}^{3\hat{I}'}$ T cells in melanoma patients display critical perturbations with prognostic impact on clinical outcome. Oncolmmunology, 2019, 8, 1601483.	2.1	32
12	Circulating and Hepatic BDCA1+, BDCA2+, and BDCA3+ Dendritic Cells Are Differentially Subverted in Patients With Chronic HBV Infection. Frontiers in Immunology, 2019, 10, 112.	2.2	22
13	Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment. Clinical and Translational Gastroenterology, 2019, 10, e00058.	1.3	38
14	The avidity of tumorâ€specific T cells amplified by a plasmacytoid dendritic cellâ€based assay can predict the clinical evolution of melanoma patients. Pigment Cell and Melanoma Research, 2018, 31, 82-94.	1.5	3
15	Cancer Vaccines: Dendritic Cell-Based Vaccines and Related Approaches. , 2018, , 260-260.		O
16	Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model. Molecular Therapy, 2017, 25, 534-546.	3.7	18
17	Co-delivery of the NKT agonist $\hat{l}$ ±-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses. Oncolmmunology, 2017, 6, e1339855.	2.1	45
18	Pegylated Interferon $\hat{1}\pm -2a$ Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion. PLoS ONE, 2016, 11, e0158297.	1,1	22

#	Article	IF	CITATIONS
19	Melanoma dormancy in a mouse model is linked to GILZ/FOXO3A-dependent quiescence of disseminated stem-like cells. Scientific Reports, 2016, 6, 30405.	1.6	25
20	Melanoma hijacks plasmacytoid dendritic cells to promote its own progression. Oncolmmunology, 2014, 3, e27402.	2.1	28
21	pDCs efficiently process synthetic long peptides to induce functional virus―and tumourâ€specific Tâ€cell responses. European Journal of Immunology, 2014, 44, 2880-2892.	1.6	16
22	X-Chromosome Complement and Estrogen Receptor Signaling Independently Contribute to the Enhanced TLR7-Mediated IFN-α Production of Plasmacytoid Dendritic Cells from Women. Journal of Immunology, 2014, 193, 5444-5452.	0.4	176
23	Imiquimod Inhibits Melanoma Development by Promoting pDC Cytotoxic Functions and Impeding Tumor Vascularization. Journal of Investigative Dermatology, 2014, 134, 2551-2561.	0.3	65
24	Paramagnetic nanoparticles to track and quantify in vivo immune human therapeutic cells. Nanoscale, 2013, 5, 11409.	2.8	12
25	A Safe Bacterial Microsyringe for In Vivo Antigen Delivery and Immunotherapy. Molecular Therapy, 2013, 21, 1076-1086.	3.7	17
26	Plasmacytoid Dendritic Cells Support Melanoma Progression by Promoting Th2 and Regulatory Immunity through OX40L and ICOSL. Cancer Immunology Research, 2013, 1, 402-415.	1.6	146
27	Upregulation of Adhesion Molecules on Leukemia Targets Improves the Efficacy of Cytotoxic T Cells Transduced With Chimeric Anti-CD19 Receptor. Journal of Immunotherapy, 2013, 36, 181-189.	1.2	11
28	HLA-A*0201 + Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients. Journal of Investigative Dermatology, 2012, 132, 2395-2406.	0.3	37
29	Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection. Hepatology, 2012, 56, 1706-1718.	3.6	34
30	Altered Functions of Plasmacytoid Dendritic Cells and Reduced Cytolytic Activity of Natural Killer Cells in Patients With Chronic HBV Infection. Gastroenterology, 2012, 143, 1586-1596.e8.	0.6	115
31	Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. Journal of Experimental Medicine, 2011, 208, 479-490.	4.2	233
32	Plasmacytoid dendritic cells andÂdermatological disorders: focus onÂtheirÂrole inÂautoimmunity andÂcancer. European Journal of Dermatology, 2010, 20, 016-023.	0.3	54
33	A Novel Cancer Vaccine Strategy Based on HLA-A*0201 Matched Allogeneic Plasmacytoid Dendritic Cells. PLoS ONE, 2010, 5, e10458.	1.1	47
34	Exploration of the Lysis Mechanisms of Leukaemic Blasts by Chimaeric T-Cells. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-9.	3.0	8
35	Characterization of Circulating Dendritic Cells in Melanoma: Role of CCR6 in Plasmacytoid Dendritic Cell Recruitment to the Tumor. Journal of Investigative Dermatology, 2010, 130, 1646-1656.	0.3	86
36	Breast cancer instructs dendritic cells to prime interleukin 13–secreting CD4+ T cells that facilitate tumor development. Journal of Experimental Medicine, 2007, 204, 1037-1047.	4.2	296

#	Article	IF	CITATION
37	Humanized mice for the development and testing of human vaccines. Expert Opinion on Drug Discovery, 2007, 2, 949-960.	2.5	5
38	Dendritic cell subsets in health and disease. Immunological Reviews, 2007, 219, 118-142.	2.8	370
39	T-Cell Homing to the Pancreas in Autoimmune Mouse Models of Diabetes: In Vivo MR Imaging. Radiology, 2005, 236, 579-587.	3.6	44
40	Immunotherapy Via Dendritic Cells. , 2005, 560, 105-114.		47
41	Early events in islets and pancreatic lymph nodes in autoimmune diabetes. Journal of Autoimmunity, 2004, 23, 27-35.	3.0	33
42	$\hat{l}_{\pm}4$ Integrins and L-selectin Differently Orchestrate T-cell Activity During Diabetes Prevention Following Oral Administration of CTB-insulin. Journal of Autoimmunity, 2002, 19, 223-232.	3.0	15
43	Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice. Clinical and Experimental Immunology, 2002, 130, 204-211.	1.1	56